Preparing and administering injectable antibiotics: How to avoid playing God;Préparation et administration des antibiotiques par voie injectable : comment éviter de jouer à l'apprenti sorcier

Medecine et Maladies Infectieuses

Volumn 46, Issue 5, 2016, Pages 242-268

  Longuet, P ^a   Lecapitaine, A L ^b   Cassard, B ^c   Batista, R ^d   Gauzit, R ^d   Lesprit, P ^e   Haddad, R ^f   Vanjak, D ^g   Diamantis, S ^c  

^a CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^b Centre Hospitalier Robert Ballanger CHRB   (France)

^c Groupe Hospitalier Sud Ile de France   (France)

^d Institut Cochin   (France)

^e FOCH HOSPITAL   (France)

^f HÔPITAL ANTOINE BÉCLÈRE   (France)

^g INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ARTICLE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG CHOICE; GOOD CLINICAL PRACTICE; HUMAN; MEDICAL PRACTICE; NURSE ATTITUDE; PATIENT CARE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PROFESSIONAL KNOWLEDGE; PROTOCOL COMPLIANCE; TREATMENT DURATION; AMBULATORY CARE; ANTIBIOTIC RESISTANCE; DRUG FORMULATION; DRUG STABILITY; FRANCE; INAPPROPRIATE PRESCRIBING; INFUSION PUMP; INJECTION; INTRAVENOUS DRUG ADMINISTRATION; POWDER; PROCEDURES; SOLUBILITY; SOLUTION AND SOLUBILITY; STANDARDS;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; DRUG COMPOUNDING; DRUG RESISTANCE, MICROBIAL; DRUG STABILITY; FRANCE; HUMANS; INAPPROPRIATE PRESCRIBING; INFUSION PUMPS; INFUSIONS, INTRAVENOUS; INJECTIONS; POWDERS; SOLUBILITY; SOLUTIONS;

EID: 84963945164     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2016.01.010     Document Type: Article

References (56)

1. [1] Craig, W.A., Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17 (2003), 479–501.
2. [2] Van Herendael, B., Jeurissen, A., Tulkens, P.M., Vlieghe, E., Verbrugghe, W., Jorens, P.G., et al. Continuous infusion of antibiotics in the critically ill: the new holy grail for beta-lactams and vancomycin?. Ann Intensive Care, 2, 2012, 22.
3. [3] Gilchrist, M., Seaton, R.A., Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: challenges and checklists. J Antimicrob Chemother 70 (2015), 965–970.
4. [4] Bourget, P., Amin, A., Dupont, C., Abely, M., Desmazes-Dufeu, N., Dubus, J.C., et al. How to minimize toxic exposure to pyridine during continuous infusion of ceftazidime in patients with cystic fibrosis?. Antimicrob Agents Chemother 58 (2014), 2849–2855.
5. [5] Servais, H., Tulkens, P.M., Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 45 (2001), 2643–2647.
6. [6] Stewart, J.T., Warren, F.W., Johnson, S.M., Fox, J.L., Mullaney, J., Stability of ceftazidime in plastic syringes and glass vials under various storage conditions. J Am Hosp Pharm 49 (1992), 2765–2768.
7. [7] Raverdy, V., Ampe, E., Hecq, J.D., Tulkens, P.M., Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 68 (2013), 1179–1182.
8. [8] Guide de reconstitution et d'administration des principaux anti-infectieux injectables OMEDIT Centre. http://www.omedit-centre.fr/.
9. [9] Guide d'administration des anti-infectieux injectables chez l'adulte. Pharmacie des hôpitaux universitaires de Genève. http://pharmacie.hug-ge.ch/.
10. [10] Ansm. Le résumé des caractéristiques du produit. http://ansm.sante.fr/Services/Repertoire-des-medicaments [RCP révision 2014].
11. [11] Thériaque. Banque de donnée sur les médicaments. http://www.theriaque.org/.
12. [12] Stabilis. Stabilité et compatibilité des médicaments. http://www.stabilis.org/.
13. [13] OMEDIT Poitou-Charentes. Observatoire du médicament, des dispositifs médicaux et de l'innovation thérapeutique–Poitou Charentes. https://omedit.sante-poitou-charentes.fr.
14. [14] Zbrozek, A.S., Marble, D.A., Bosso, J.A., Bair, J.N., Townsend, R.J., Compatibility and stability of clindamycin phosphate – aminoglycoside combinations within polypropylene syringes. Drug Intell Clin Pharm 21 (1987), 806–810.
15. [15] Roberts, J.A., Taccone, F.S., Udy, A.A., Vincent, J.L., Jacobs, F., Lipman, J., Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 55 (2011), 2704–2709.
16. [16] Saugel, B., Nowack, M.C., Hapfelmeier, A., Umgelter, A., Schultheiss, C., Thies, P., et al. Continuous intravenous administration of vancomycin in medical intensive care unit patients. J Crit Care 28 (2013), 9–13.
17. [17] Wood, M.J., Lund, R., Beavan, M., Stability of vancomycin in plastic syringes measured by high-performance liquid chromatography. J Clin Pharm Ther 20 (1995), 319–325.
18. [18] Cook, B., Hill, S.A., Lynn, B., The stability of amoxicillin sodium in intravenous infusion fluids. J Clin Hosp Pharm 7 (1982), 245–250.
19. [19] Arlicot, N., Rochefort, G.Y., Schlecht, D., Lamoureux, F., Marchand, S., Antier, D., Stability of antibiotics in portable pumps used for bronchial superinfection: guidelines for prescribers. Pediatrics 120 (2007), 1255–1259.
20. [20] Prescott, W.A., Gentile, A.E., Nagel, J.L., Pettit, R.S., Continuous-infusion antipseudomonal beta-lactam therapy in patients with cystic fibrosis. P T 36 (2011), 723–726.
21. [21] Viaene, E., Chanteux, H., Servais, H., Mingeot-Leclercq, M.P., Tulkens, P.M., Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 46 (2002), 2327–2332.
22. [22] Vinks, A.A., Touw, D.J., van Rossen, R.C., Heijerman, H.G., Bakker, W., Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatment (HIVAT). Pharm World Sci 18 (1996), 74–77.
23. [23] Donnelly, R.F., Stability of cefazolin sodium in polypropylene syringes and polyvinylchloride minibags. Can J Hosp Pharm 64 (2011), 241–245.
24. [24] Pharmaceutical Partners of Canada Inc, Cefazolin. 2015 http://fresenius-kabi.ca/wp-content/uploads/2015/01/EN_WebInsert_Cefazolin.
25. [25] Walker, S.E., Iazzetta, J., Law, S., Biniecki, K., Stability of commonly used antibiotic solutions in an elastomeric infusion device. Can J Hosp Pharm 63 (2010), 212–224.
26. [26] Zeller, V., Durand, F., Kitzis, M.D., Lhotellier, L., Ziza, J.M., Mamoudy, P., et al. Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations. Antimicrob Agents Chemother 53 (2009), 883–887.
27. [27] Baririan, N., Chanteux, H., Viaene, E., Servais, H., Tulkens, P.M., Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 51 (2003), 651–658.
28. [28] Rabouan Guyon, S., Guet, A., Courtois, P., Barthes, D., Stability study of cefepime in different infusion solutions. Int J Pharm 154 (1997), 185–190.
29. [29] Sprauten, F., Beringer, P.M., Louie, S.G., Synold, T.W., Gill, M.A., Stability and antibacterial activity of cefepime during continuous infusion. Antimicrob Agents Chemother 47 (2003), 1991–1994.
30. [30] Stewart, J.T., Maddox, F.C., Warren, F.W., Stability of cefepime hydrochloride in polypropylene syringes. Am J Health Syst Pharm, 56, 1999, 1134.
31. [31] Foley, P.T., Bosso, J.A., Bair, J.N., Townsend, R.J., Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures. Am J Hosp Pharm 42 (1985), 839–843.
32. [32] Gupta, V.D., Stability of cefotaxime sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compd 6 (2002), 234–236.
33. [33] van Zanten, A.R., Oudijk, M., Nohlmans-Paulssen, M.K., van der Meer, Y.G., Girbes, A.R., Polderman, K.H., Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol 63 (2007), 100–109.
34. [34] Lüthy, R., Münch, R., Blaser, J., Bhend, H., Siegenthaler, W., Human pharmacology of cefotaxime (HR 756), a new cephalosporin. Antimicrob Agents Chemother 16 (1979), 127–133.
35. [35] O'Brien, M.J., Portnoff, J.B., Cohen, E.M., Cefoxitin sodium compatibility with intravenous infusions and additives. Am J Hosp Pharm 36 (1979), 33–38.
36. [36] Marble, D.A., Bosso, J.A., Towsend, R.J., Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium or piperacillin sodium in two intravenous solutions. Am J Hosp Pharm 43 (1986), 1732–1736.
37. [37] Das Gupta, V., Parasrampuria, J., Bethea, C., Wright, W., Stability of clindamycin phosphate in dextrose and saline solutions. Can J Hosp Pharm 42 (1989), 109–112.
38. [38] Marble, D.A., Bosso, J.A., Townsend, R.J., Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles. Drug Intell Clin Pharm 22 (1988), 54–57.
39. [39] Porter, W.R., Johnson, C.A., Cohon, M.S., Gillespie, W., Compatibility and stability of clindamycin phosphate with intravenous fluids. Am J Hosp Pharm 40 (1983), 91–94.
40. [40] Zeller, V., Dzeing-Ella, A., Kitzis, M.D., Ziza, J.M., Mamoudy, P., Desplaces, N., Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother 54 (2010), 88–92.
41. [41] Walker, S.E., Dufour, A., Iazzetta, J., Concentration and solution dependent stability of cloxacillin intravenous solutions. Can J Hosp Pharm 51 (1998), 13–19.
42. [42] Keel, R.A., Sutherland, C.A., Crandon, J.L., Nicolau, D.P., Stability of doripenem, imipenem and meropenem at elevated room temperatures. Int J Antimicrob Agents 37 (2011), 184–185.
43. [43] Berthoin, K., Le Duff, C.S., Marchand-Brynaert, J., Carryn, S., Tulkens, P.M., Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 65 (2010), 1073–1075.
44. [44] Carlier, M., Stove, V., Verstraete, A.G., De Waele, J., Stability of generic brands of meropenem reconstituted in isotonic saline. Minerva Anestesiol 81 (2015), 283–287.
45. [45] Jaruratanasirikul, S., Thengyai, S., Wongpoowarak, W., Wattanavijitkul, T., Tangkitwanitjaroen, K., Sukarnjanaset, W., et al. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother 59 (2015), 2995–3001.
46. [46] Jehl, F., Levêque, D., Perfusion continue des bêtalactamines : intérêts, inconvénients, modalités pratiques. Réanimation 18 (2009), 343–352.
47. [47] Manning, L., Wright, C., Ingram, P.R., Whitmore, T.J., Heath, C.H., Manson, I., et al. Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability. PloS One, 9, 2014, e102023.
48. [48] Roberts, J.A., Kirkpatrick, C.M., Roberts, M.S., Robertson, T.A., Dalley, A.J., Lipman, J., Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64 (2009), 142–150.
49. [49] Hossain, M.A., Friciu, M., Aubin, S., Leclair, G., Stability of penicillin G sodium diluted with 0.9% sodium chloride injection or 5% dextrose injection and stored in polyvinyl chloride bag containers and elastomeric pump containers. Am J Health Syst Pharm 71 (2014), 669–673.
50. [50] Vella-Brincat, J.W., Begg, E.J., Gallagher, K., Kirkpatrick, C.M., Zhang, M., Frampton, C., et al. Stability of benzylpenicillin during continuous home intravenous therapy. J Antimicrob Chemother 53 (2004), 675–677.
51. [51] Stiles, M.L., Allen, L.V., Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs. Am J Health Syst Pharm 54 (1997), 1068–1070.
52. [52] Roberts, J.A., Kirkpatrick, C.M., Roberts, M.S., Dalley, A.J., Lipman, J., First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 35 (2010), 156–163.
53. [53] Donnelly, R.F., Stability of aseptically prepared tazocin solutions in polyvinyl chloride bags. Can J Hosp Pharm 62:3 (2009), 226–231.
54. [54] De Jongh, R., Hens, R., Basma, V., Mouton, J.W., Tulkens, P.M., Carryn, S., Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 61 (2008), 382–388.
55. [55] Laterre, P.F., Wittebole, X., Van de Velde, S., Muller, A.E., Mouton, J.W., Carryn, S., et al. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. J Antimicrob Chemother 70 (2015), 891–898.
56. [56] Young, D., Fadiran, E.O., Chang, K.T., Sagraves, R., Forrester, L., Stability of ticarcillin disodium in polypropylene syringes. Am J Health Syst Pharm 52 (1995), 890–892.